Inhibrx Biosciences, Inc. INBX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s additional paid-in capital?
- Inhibrx Biosciences, Inc. (INBX) reported additional paid-in capital of $258.59M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s additional paid-in capital changed year-over-year?
- Inhibrx Biosciences, Inc.'s additional paid-in capital increased by 6.0% year-over-year, from $243.89M to $258.59M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s additional paid-in capital has grown at a -37.8% compound annual growth rate (CAGR), from $657.23M to $254.18M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.